Avanafil for the treatment of erectile dysfunction
- 2 August 2016
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 9 (9) , 1163-1170
Abstract
Introduction: Erectile dysfunction (ED) affects millions of men worldwide, and the incidence of ED will continue to increase as the aging population grows. The first generation of phosphodiesterase-5 (PDE5) inhibitors, the mainstay of oral ED therapy, has revolutionized the treatment of this condition, but not without some drawbacks. Avanafil, the only United States and European Union-approved second-generation PDE5 inhibitor, is a safe and efficacious alternative to its predecessors. Areas covered: We reviewed the current and most up-to-date literature regarding Avanafil, as well as the pivotal trials that measured efficacy and tolerability. As Avanafil is still a relatively new drug, there is still a relative paucity of literature which inherently limited the search parameters. We searched the PUBMED database for articles detailing the clinical trials, chemistry, pharmacokinetics and dynamics, safety, and efficacy of the drug. Expert commentary: Avanafil’s unique pharmacologic profile both narrows and minimizes side effects while reducing the time of onset of action to half of its closest competitor, providing men who suffer with ED a return to a more spontaneous sex life.Keywords
This publication has 35 references indexed in Scilit:
- Avanafil for the treatment of erectile dysfunction: initial data and clinical key propertiesTherapeutic Advances in Urology, 2012
- Prevalence and Risk Factors for Erectile Dysfunction in the USThe American Journal of Medicine, 2007
- Phosphodiesterase type 5 inhibitors’ extended duration of response as a variable in the treatment of erectile dysfunctionInternational Journal Of Impotence Research, 2006
- Physiology of Penile Erection and Pathophysiology of Erectile DysfunctionUrologic Clinics of North America, 2005
- CHAPTER 1: THE MANAGEMENT OF ERECTILE DYSFUNCTION: AN AUA UPDATEJournal of Urology, 2005
- Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunctionExpert Opinion on Pharmacotherapy, 2005
- UK management guidelines for erectile dysfunctionBMJ, 2000
- INCIDENCE OF ERECTILE DYSFUNCTION IN MEN 40 TO 69 YEARS OLD: LONGITUDINAL RESULTS FROM THE MASSACHUSETTS MALE AGING STUDYJournal of Urology, 2000
- The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequencesBJU International, 1999
- ImpotenceJAMA, 1993